Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | IDH1 mut IDH2 mut |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07075016 | Phase III | Azacitidine + Ivosidenib + Venetoclax Azacitidine + Ivosidenib | Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy (EVOLVE 1) | Recruiting | SWE | NOR | NLD | LTU | ITA | IRL | GBR | FRA | FIN | EST | ESP | DNK | DEU | CHE | BEL | AUT | 0 |